Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Shamji, Mohamed H.; Kappen, Jasper H; Akdiş, Mübeccel; Jensen‐Jarolim, Erika; Knol, Edward F.; Kleine‐Tebbe, Jörg; Bohle, Barbara; Chaker, Adam; Till, Stephen J.; Valenta, Rudolf; Poulsen, Lars K.; Calderón, Moisés A.; Demoly, Pascal; Pfaar, Oliver; Jacobsen, Lars; Durham, Stephen R.; Schmidt‐Weber, Carsten B.

doi:10.1111/all.13138

Cited by 301 publications

(423 citation statements)

References 193 publications

(212 reference statements)

Supporting

Mentioning

367

Contrasting

Unclassified

Order By: Relevance

“…We need biomarkers to predict and quantify the effectiveness of AIT to assist in patient selection. 222 Suboptimal adherence with AIT is likely to impact on its effectiveness; novel approaches to improve effectiveness should be developed in partnership with patients. Also, to allow better comparison of safety between approaches, studies need to use a unified approach to classifying side-effects is required.…”

mentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

Self Cite

563

762

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

mentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

Self Cite

563

762

View full text Add to dashboard Cite

show abstract

“…Similar points can be made regarding identifying any proposed biomarkers for allergic disorders and asthma, as described in recent papers on the potential use of immune monitoring and other data to improve the classification and management of allergic disease, including allergic rhinoconjunctivitis[63] and asthma[36]. As noted by Muraro et al, the heterogeneity of asthma, rhinitis, and AD biomarkers, and variation in the onset, clinical presentation and rates of remission or progression in these diseases combine to generate difficulties in determining the appropriate clinical management strategies, and in selecting biomarkers of therapeutic efficacy[36].…”

Section: Therapy Selection and Monitoringmentioning

confidence: 96%

Immune monitoring for precision medicine in allergy and asthma

Boyd

Hoh

Galli

2017

Current Opinion in Immunology

View full text Add to dashboard Cite

“Precision Medicine” embodies the analyses of extensive data collected from patients and their environments to identify and apply patient-specific prophylactic strategies and medical treatments to improve clinical outcomes and healthcare cost-effectiveness. Many new methods have been developed for evaluating the activity of the human immune system. Such “immune monitoring” approaches are now being used in studies of allergy and asthma in the hope of identifying better correlates of disease status, predictors of therapeutic outcomes, and potential side-effects of treatment. Together with analyses of family histories, genetic and other biometric data, and measurements of exposures to environmental and other risk factors for developing or exacerbating disease, immune monitoring approaches promise to enable “Precision Medicine” for allergic diseases and asthma.

show abstract

“…The etiology of allergic disease is poorly understood, and its potential biologic mechanisms are still unclear . As other allergic inflammatory diseases, AR is considered to have complex associations with genetic and environment factors in etiology.…”

Section: Risk Factorsmentioning

confidence: 99%

Recent developments and highlights in allergic rhinitis

Meng

Wang

Zhang

2019

Allergy

125

105

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a disease with high prevalence all over the world and therefore needs to be thoroughly investigated and treated accordingly. The mechanisms underlying the pathology and treatment of AR have been widely studied, but many aspects remain unclear and warrant further investigations. This review presents an overview of recently published papers highlighting the risk factors, mechanisms, and treatment of AR. Additionally, recent studies discussing the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics in AR are also covered. K E Y W O R D Sallergic rhinitis, biologics, epigenetics, risk factors, treatment | 2321 MENG Et al.

show abstract

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Cited by 301 publications

References 193 publications

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Immune monitoring for precision medicine in allergy and asthma

Recent developments and highlights in allergic rhinitis

Contact Info

Product

Resources

About